新型长效重组促卵泡素的纯化和性质及药代动力学研究

doi:10.13523/j.cb.20140208

中国生物工程杂志

2014, Vol. 34

Issue (2): 45-51 DOI: 10.13523/j.cb.20140208

研究报告

新型长效重组促卵泡素的纯化和性质及药代动力学研究

杨凡¹, 黄虎¹, 李屹晨², 邓衡露², 吴茂柏², 钟翎^1,3, 侯永敏^1,2

1. 中山大学药学院广州 510006;
2. 广州优联康医药科技有限公司广州 510006;
3. 深圳市药品不良反应监测中心深圳 518024

Purification, Characterization and Pharmacokinetic Study of a Novel Long-acting Follicle-stimulating Hormone

YANG Fan¹, HUANG Hu¹, LI Yi-chen², DENG Heng-lu², WU Mao-bo², ZHONG Ling^1,3, HOU Yong-min^1,2

1. School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China;
2. Unicomed Pharma Ltd., Guangzhou 510006, China;
3. Shenzhen Drug Administration, Shenzhen 518024, China

全文: PDF(756 KB) HTML

摘要： 促卵泡素（Follicle-stimulating hormone，FSH）用于治疗男女不孕不育症，由于FSH的半衰期较短，需要频繁注射给药，因此制备长效FSH制剂一直是该类药物的研发方向。首次将来自绒促性素（human chorionic gonadotropin，HCG）中的羧基端肽（carboxy-terminal peptide，CTP）和人免疫球蛋白G2（immunoglobulin G2，IgG2 ）Fc片段变体（vFc）与单链FSH有序连接，通过基因工程和哺乳动物细胞培养技术实现了其在中国仓鼠卵巢细胞中的稳定表达，然后利用Protein A柱层析手段进行纯化，制备了新型重组FSH-CTP-vFc融合蛋白，同时分析了不同细胞培养时间表达的重组融合蛋白的理化性质和体内外活性。动物试验结果表明，纯化的FSH-CTP-vFc融合蛋白具有显著的体内生物活性，药代动力学分析显示该重组融合蛋白的半衰期是重组FSH的近10倍。这种新型长效重组FSH-CTP-vFc融合蛋白在临床上可大大减少注射次数和患者痛苦，提高患者用药依从性。

关键词： 重组人促卵泡素; 长效; CTP; vFc融合蛋白; 药代动力学

Abstract: Follicle-stimulating hormone (FSH) has been utilized to treat male and female infertility. However, frequent injection of FSH to patients is required due to its short serum half-life. Developing a long-acting recombinant FSH is clinically desirable. A DNA construct containing FSH-CTP-vFc was made by fusing the coding sequence of carboxyl-terminal peptide (CTP) of the β-subunit of human chorionic gonadotropin and a variant of human Immunoglobulin G2(IgG2) Fc fragment (vFc) into FSH gene. The DNA construct was transfected into Chinese Hamster Ovary (CHO) cells, and cell clones with highly and stably expressed FSH-CTP-vFc fusion protein were selected. The cultured medium of cell was collected for protein purification by protein A based chromatography. Biochemical and physical characterization were performed for the fusion proteins purified from the samples of different culture time. ELISA assay and animal study shows that the purified FSH-CTP-vFc protein has significant activity in vitro and in vivo. Pharmacokinetic research demonstrates that the serum half-life of the fusion protein is almost ten fold of the recombinant FSH's. Obviously, this novel long-acting FSH-CTP-vFc protein could greatly reduce the injection frequency and improve the patient compliance.

Key words: Recombinant FSH Long-acting CTP vFc fusion protein Pharmacokinetics

收稿日期: 2013-12-03 出版日期: 2014-02-25

ZTFLH:

Q819

基金资助: 广州市创业领军人才创业启动基金资助项目（LCY201305）

通讯作者: 钟翎, 侯永敏 E-mail: ray091609@163.com;lsszhl@mail.sysu.edu.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨凡
	黄虎
	李屹晨
	邓衡露
	吴茂柏
	钟翎
	侯永敏

引用本文:

杨凡, 黄虎, 李屹晨, 邓衡露, 吴茂柏, 钟翎, 侯永敏. 新型长效重组促卵泡素的纯化和性质及药代动力学研究[J]. 中国生物工程杂志, 2014, 34(2): 45-51.

YANG Fan, HUANG Hu, LI Yi-chen, DENG Heng-lu, WU Mao-bo, ZHONG Ling, HOU Yong-min. Purification, Characterization and Pharmacokinetic Study of a Novel Long-acting Follicle-stimulating Hormone. China Biotechnology, 2014, 34(2): 45-51.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20140208 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I2/45

[1] 范俊,邓晓惠. 卵泡刺激素研究进展.生殖与避孕, 1998, 18(2): 122-125. Fan J, Deng X H. Research progress of follicle stimulating hormone. Journal of Reproduction and Contraception, 1998, 18(2):122-125.
[2] Devroey P, Fauser B C, Platteau P, et al. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab, 2004, 89(5): 2062-2070.
[3] Duijkers I J, Klipping C, Boerrigter PJ, et al. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod, 2002, 17(8): 1987-1993.
[4] Ben-Menahem D, Grotjan H E. Strategies for construction of luteinizing hormone beta subunit analogs with carboxyl terminal extensions in non-primate, non-equid mammalian species. Mol Cell Endocrinol, 2007, 260-262: 205-211.
[5] Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health, 2011, 3: 243-255.
[6] Fauser B C, Mannaerts B M, Devroey P, et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update, 2009, 15(3): 309-321.
[7] Dumont J A, Low S C, Peters R T, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs, 2006, 20(3): 151-160.
[8] Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol, 2010, 184(4): 1968-1976.
[9] Bitonti A J, Dumont J A, Low S C, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A, 2004, 101(26): 9763-9768.
[10] Council of Europe Strasbourg. European Pharmacopoeia. 2008,Vol V:69.
[11] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录 XIV130-147. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix XIV130-147.
[12] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录VI C35. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix VI C35.
[13] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录IV D24. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix VI D24
[14] Hakola K, Haavisto A M, Pierroz D D, et al. Recombinant forms of rat and human luteinizing hormone and follicle-stimulating hormone; comparison of functions in vitro and in vivo. J Endocrinol, 1998, 158(3): 441-448.
[15] Verbost P, Sloot W N, Rose U M, et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol, 2011,651(1-3):227-233.
[16] Mascarenhas M N, Flaxman S R, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med, 2012, 9(12): e1001356.
[17] Lo K M, Sudo Y, Chen J, et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng, 1998, 11(6): 495-500.
[18] Lightle S, Aykent S, Lacher N, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci, 2010, 19(4): 753-762.

[1]	邵莉, 马晓慧, 王相阳, 徐寒梅. 长效化融合蛋白药物及其药动学分析技术的研究进展[J]. 中国生物工程杂志, 2017, 37(4): 83-88.
[2]	刘立平, 张纯, 殷爽, 王祺, 张耀, 余蓉, 刘永东, 苏志国. 白蛋白结合肽-多柔比星耦合物的设计、制备、表征及初步评价[J]. 中国生物工程杂志, 2017, 37(4): 68-75.
[3]	殷爽, 冯翠, 张纯, 王祺, 王健, 余蓉, 刘永东, 苏志国. 转铁蛋白-PEG-睫状神经营养因子的制备及其生物活性评价[J]. 中国生物工程杂志, 2016, 36(4): 43-49.
[4]	孙娇梦, 许传营, 张忠辉, 王婧, 俞雁, 韩伟. 重组人中期因子midkine对大鼠膝关节软骨部分损伤的修复作用[J]. 中国生物工程杂志, 2010, 30(11): 1-5.
[5]	田硕姚文兵周敏毅李洁宋文进徐晨. 新型集成干扰素-人血清白蛋白融合蛋白在毕赤酵母中的分泌表达和纯化[J]. 中国生物工程杂志, 2010, 30(06): 34-37.
[6]	牛晓霞,周敏毅,刘金毅,孙超,钟茜,吴晓东. 聚乙二醇定点修饰集成干扰素突变体Ⅱ[J]. 中国生物工程杂志, 2008, 28(4): 17-20.
[7]	戚楠,马清钧. 长效重组蛋白药物的研究进展[J]. 中国生物工程杂志, 2006, 26(02): 79-82.
[8]	喻光荣, 蒋俶, 冯文华, 沈卫英, 蒋文珏, 申庆祥. hCGβ-CTP37多聚体的表达、纯化及其多克隆抗体的制备[J]. 中国生物工程杂志, 2005, 25(11): 26-31.
[9]	汪小凤, 郑青. 生物技术药物药代动力学研究的方法学和实验设计[J]. 中国生物工程杂志, 2004, 24(2): 80-83,87.

Viewed

Full text

Abstract

Cited

Shared

Discussed